AHA: AstraZeneca's Farxiga outcomes data looks even better in patients without diabetes

Turns out AstraZeneca's "paradigm shifting" outcomes data for SLGT2 med Farxiga show an even greater cardiovascular benefit for patients who don't have diabetes than those who do—and this for a drug designed specifically to treat the disease.